Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Tüting

Showing results (1-10 of 154) with videos related to

Pageof 16
Sort By:
Pigment Cell & Melanoma Research|August 24, 2010
Of swords and ploughshares: immunosurveillance and inflammation in melanomaThomas Tüting
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 11, 2008
[New directions in melanoma therapy]Thomas Tüting
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 5, 2016
Die tumorimmunologische Revolution in der Behandlung des fortgeschrittenen MelanomsThomas Tüting
Pigment Cell & Melanoma Research|April 27, 2013
T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patientsThomas Tüting
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|January 13, 2019
[Personalized medicine]Kilian Eyerich, Thomas Tüting
Experimental Dermatology|April 18, 2007
Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approachesJoerg Wenzel, Thomas Tüting
Methods in Molecular Biology (Clifton, N.J.)|October 30, 2012
Biolistic DNA vaccination against melanomaJulia Steitz, Thomas Tüting
Trends in Immunology|May 7, 2016
Inflammation-Induced Plasticity in Melanoma Therapy and MetastasisMichael Hölzel, Thomas Tüting
The Journal of Investigative Dermatology|April 18, 2008
An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in "interface dermatitis"Joerg Wenzel, Thomas Tüting
Immunity|February 21, 2019
Live or Let Die: T Cell Survival in Cancer ImmunotherapyJanne Ruotsalainen, Thomas Tüting
Pageof 16

Showing results (1-10 of 154) with videos related to

Sort By:
Pageof 16
Pigment Cell & Melanoma Research|August 24, 2010
Of swords and ploughshares: immunosurveillance and inflammation in melanomaThomas Tüting
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 11, 2008
[New directions in melanoma therapy]Thomas Tüting
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 5, 2016
Die tumorimmunologische Revolution in der Behandlung des fortgeschrittenen MelanomsThomas Tüting
Pigment Cell & Melanoma Research|April 27, 2013
T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patientsThomas Tüting
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|January 13, 2019
[Personalized medicine]Kilian Eyerich, Thomas Tüting
Experimental Dermatology|April 18, 2007
Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approachesJoerg Wenzel, Thomas Tüting
Methods in Molecular Biology (Clifton, N.J.)|October 30, 2012
Biolistic DNA vaccination against melanomaJulia Steitz, Thomas Tüting
Trends in Immunology|May 7, 2016
Inflammation-Induced Plasticity in Melanoma Therapy and MetastasisMichael Hölzel, Thomas Tüting
The Journal of Investigative Dermatology|April 18, 2008
An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in "interface dermatitis"Joerg Wenzel, Thomas Tüting
Immunity|February 21, 2019
Live or Let Die: T Cell Survival in Cancer ImmunotherapyJanne Ruotsalainen, Thomas Tüting
Pageof 16